| Christopher D Murphy, DPT | |
|
2300 53rd Ave Ll02, Bettendorf, IA 52722 | |
| (563) 449-7000 | |
| (563) 449-7099 |
| Full Name | Christopher D Murphy |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 12 Years |
| Location | 2300 53rd Ave Ll02, Bettendorf, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376881185 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 005119 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rock Valley Physical Therapy Center | 9638087877 | 188 |
News Archive
A new study, by researchers Drs. Boers, Afzali and Conrod who are affiliated with CHU Sainte-Justine Research Center and the Department of Psychiatry at the University of Montreal, reveals that social media use, television viewing and computer use, but not video gaming, are linked to an increase in anxiety symptoms among adolescents.
Pathogenic or likely pathogenic alterations in these 14 DNA repair genes were less likely to be detected in African Americans as compared to Caucasians.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When Grace Jividen competed in the 1992 Olympics in Barcelona, Spain, she couldn't hear her opponent's breathing, which she believes could have given her the edge in her judo competitions. Now, the former member of the 1992 U.S. women's judo team and holder of more than 41 medals from international competitions and a sixth degree black belt has the edge she was looking for thanks to Lyric, the world's first 100 percent invisible extended wear hearing device.
Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.
› Verified 8 days ago
| Provider Name | Ora Orthopedics Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1962481861 PECOS PAC ID: 6406741784 Enrollment ID: O20040216001316 |
News Archive
A new study, by researchers Drs. Boers, Afzali and Conrod who are affiliated with CHU Sainte-Justine Research Center and the Department of Psychiatry at the University of Montreal, reveals that social media use, television viewing and computer use, but not video gaming, are linked to an increase in anxiety symptoms among adolescents.
Pathogenic or likely pathogenic alterations in these 14 DNA repair genes were less likely to be detected in African Americans as compared to Caucasians.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When Grace Jividen competed in the 1992 Olympics in Barcelona, Spain, she couldn't hear her opponent's breathing, which she believes could have given her the edge in her judo competitions. Now, the former member of the 1992 U.S. women's judo team and holder of more than 41 medals from international competitions and a sixth degree black belt has the edge she was looking for thanks to Lyric, the world's first 100 percent invisible extended wear hearing device.
Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.
› Verified 8 days ago
| Provider Name | Rock Valley Physical Therapy Center |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1245373166 PECOS PAC ID: 9638087877 Enrollment ID: O20080513000596 |
News Archive
A new study, by researchers Drs. Boers, Afzali and Conrod who are affiliated with CHU Sainte-Justine Research Center and the Department of Psychiatry at the University of Montreal, reveals that social media use, television viewing and computer use, but not video gaming, are linked to an increase in anxiety symptoms among adolescents.
Pathogenic or likely pathogenic alterations in these 14 DNA repair genes were less likely to be detected in African Americans as compared to Caucasians.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When Grace Jividen competed in the 1992 Olympics in Barcelona, Spain, she couldn't hear her opponent's breathing, which she believes could have given her the edge in her judo competitions. Now, the former member of the 1992 U.S. women's judo team and holder of more than 41 medals from international competitions and a sixth degree black belt has the edge she was looking for thanks to Lyric, the world's first 100 percent invisible extended wear hearing device.
Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher D Murphy, DPT 850 43rd Ave Ste 100, Moline, IL 61265-8401 Ph: (309) 743-2070 | Christopher D Murphy, DPT 2300 53rd Ave Ll02, Bettendorf, IA 52722 Ph: (563) 449-7000 |
News Archive
A new study, by researchers Drs. Boers, Afzali and Conrod who are affiliated with CHU Sainte-Justine Research Center and the Department of Psychiatry at the University of Montreal, reveals that social media use, television viewing and computer use, but not video gaming, are linked to an increase in anxiety symptoms among adolescents.
Pathogenic or likely pathogenic alterations in these 14 DNA repair genes were less likely to be detected in African Americans as compared to Caucasians.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
When Grace Jividen competed in the 1992 Olympics in Barcelona, Spain, she couldn't hear her opponent's breathing, which she believes could have given her the edge in her judo competitions. Now, the former member of the 1992 U.S. women's judo team and holder of more than 41 medals from international competitions and a sixth degree black belt has the edge she was looking for thanks to Lyric, the world's first 100 percent invisible extended wear hearing device.
Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.
› Verified 8 days ago
Elizabeth Isbell, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2730 Crow Creek Road, Bettendorf, IA 52722 Phone: 563-332-7463 | |
Dr. David M Housewright, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave Ste Ll02, Bettendorf, IA 52722 Phone: 563-449-7000 Fax: 309-449-7099 | |
Jay J Richard, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2300 53rd Ave, Suite Ll02, Bettendorf, IA 52722 Phone: 563-332-4422 Fax: 563-332-0391 | |
Michael R. Harvey, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2730 Crow Creek Rd, Bettendorf, IA 52722 Phone: 563-449-9523 Fax: 563-449-9523 | |
Mrs. Abigail M Temple, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4557 Utica Ridge Rd, Bettendorf, IA 52722 Phone: 563-332-0585 | |
Mrs. Bridget Marie Blunk, P.T. Physical Therapist Medicare: Medicare Enrolled Practice Location: 2300 53rd Ave Ste Ll02, Bettendorf, IA 52722 Phone: 563-449-7000 Fax: 563-449-7099 | |
Michael Shaw, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2300 53rd Ave, Bettendorf, IA 52722 Phone: 563-332-4422 |